Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

A Functional Profiling of Microenvironmental Factors and Small Molecules Reveals Monocyte Chemoattractant Protein-1 Mediates Drug Resistance in Acute Myeloid Leukemia

Rucha V Modak, PhD, Sara J Gosline, Alisa Damnernsawad, PhD, Tamilla Nechiporuk, PhD, Ted Laderas, PhD, Guanming Wu, PhD, Paul Piehowski, Paul.Piehowski@pnnl.gov, Stephen E Kurtz, PhD, Christopher A. Eide, Jeffrey W. Tyner, PhD, Karin Rodland, rodland@ohsu.edu, Shannon K. McWeeney, PhD, Anupriya Agarwal, PhD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-141686

Published: 2020

Journal Articles

Evolution of Gilteritinib Resistance from Residual Disease to Relapse

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-139084

Published: 2020

Journal Articles

Myeloid-Lineage Enhancers Drive Oncogene Synergy and Represent a Novel Therapeutic Target in CSF3R-CEBPA Mutant AML

Theodore Braun, MD PhD, Cody Coblentz, Sarah A Carratt, PhD BS, Mariam Okhovat, PhD, Amy Foley, MEng., Zachary Schonrock, BS, Kimberly Nevonen, Rhonda E. Ries, MA, Shannon K. McWeeney, PhD, Claus Nerlov, PhD, Soheil Meshinchi, MD PhD, Lucia Carbone, PhD, Brian J. Druker, Julia E. Maxson, PhD

Blood (2019) 134 (Supplement_1): 543.

https://doi.org/10.1182/blood-2019-124773

Published: 2019

Journal Articles

Framework to Identify and Prioritize Candidate Inherited Myeloid Malignancy Germline Variants Leveraging the BEAT AML Cohort

Daniel Bottomly, Nicola Long, Fei Yang, MD, Tiffany Lee, MD, Uma Borate, MD, Beth Wilmot, PhD, Adam S DuVall, MD, Andrea Monteblanco, BS, Karina Thiel-Klare, Gabby Dewson, BA, Richard D. Press, MD PhD, Cristina E. Tognon, Brian J. Druker, Jeffrey W. Tyner, Shannon K. McWeeney, PhD, Anupriya Agarwal, PhD

Blood (2019) 134 (Supplement_1): 1407.

https://doi.org/10.1182/blood-2019-132224

Published: 2019

Journal Articles

Genome-Wide CRISPR Screening in Acute Myeloid Leukemia Cells Identifies Genes in the PI3K/AKT/mTOR and MEK/ERK Pathways That Define Sensitivity to Trametinib

Tamilla Nechiporuk, PhD, Alisa Damnernsawad, PhD, Daniel Bottomly, MS, Quinlan Morrow, BS, Suyoun Choi, Sofia Beer, Stephen E Kurtz, PhD, Shannon K. McWeeney, PhD, Jeffrey W. Tyner

Blood (2019) 134 (Supplement_1): 1395.

https://doi.org/10.1182/blood-2019-129117

Published: 2019

Journal Articles

Discovery & Characterization of Therapeutically Targetable Ntrk Point Mutations in Leukemia

Sunil K Joshi, BA, William Bisson, PhD, Kristin Qian, Ariane Huang, Kevin Watanabe-Smith, PhD, Jeffrey W. Tyner, Monika Ashok Davare, PhD, Shannon K. McWeeney, PhD, Cristina E. Tognon, Brian J. Druker

Blood (2019) 134 (Supplement_1): 1256.

https://doi.org/10.1182/blood-2019-125908

Published: 2019

Journal Articles

Genome-Wide CRISPR Screening Identifies MAPK and Mtorc Pathways As Regulators of Sorafenib Resistance in Acute Myeloid Leukemia

Alisa Damnernsawad, PhD, Tamilla Nechiporuk, PhD, Daniel Bottomly, MS, Stephen E Kurtz, PhD, Christopher A. Eide, Shannon K. McWeeney, PhD, Jeffrey W. Tyner

Blood (2019) 134 (Supplement_1): 2557.

https://doi.org/10.1182/blood-2019-128877

Published: 2019

Journal Articles

Immunogenomic Exploration of the Acute Myeloid Leukemia Microenvironment Identifies Determinants of T-Cell Fitness

Lauren K. Brady, PhD, David Soong, PhD, Evan F. Lind, PhD, Yoko Kosaka, PhD, Adam J. Lamble, MD, Michael Schaffer, PhD, Brendan P. Hodkinson, PhD, Clare Lefave, PhD, Ted Laderas, PhD, Shannon K. McWeeney, PhD, Homer Adams, III, PhD, Yann Abraham, PhD, Pegah Safabakhsh, MS, Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Fei Huang, PhD

Blood (2018) 132 (Supplement 1): 2750.

https://doi.org/10.1182/blood-2018-99-118424

Published: 2018

Journal Articles

Combining p38MAPK Inhibitors with a Second Targeted Agent Enhances Blockade of Inflammatory Signaling-Mediated Survival in Acute Myeloid Leukemia Cells

Stephen E Kurtz, PhD, Christopher A. Eide, Narain P. Dubey, Andy Kaempf, Shannon K. McWeeney, PhD, Cristina E. Tognon, PhD, Motomi Mori, PhD, Brian J. Druker, MD, Jeffrey W. Tyner, PhD, Anupriya Agarwal, PhD

Blood (2018) 132 (Supplement 1): 2726.

https://doi.org/10.1182/blood-2018-99-117537

Published: 2018

Journal Articles

Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB

Anna L. Brown, PhD BSc, Mark Armstrong, MSc, David Lawrence, Paul Wang, Peer Arts, PhD, Nicolas Duployez, PharmD, PhD, Jane Churpek, MD, Kiran Tawana, MD, Erin Degelman, MSc, BSc, Georges Natsoulis, PhD, Monica L. Guzman, PhD, Mrinal M. Patnaik, MD MBBS, Akiko Shimamura, MD PhD, Alan B. Cantor, MD PhD, Tim Ripperger, MD PhD, Brigitte Schlegelberger, MD PhD, Doris Steinemann, PhD, Courtney D. DiNardo, MD MSc, Cristina Mecucci, MD PhD, Elvira DRP Velloso, MD PhD, Fabio PS Santos, MD, Marcela CA Silva, Uma Borate, MD, Shannon K. McWeeney, PhD, Grzegorz Nalepa, MD PhD, Susanne Ragg, MD PhD, Erika Mijin Kwon, PhD, Anupriya Agarwal, PhD, Stephen Langabeer, PhD, Jeffery M. Klco, MD PhD, Jun J. Yang, PhD, Cecily Forsyth, FRACP, FRCPA, MBBS, Sally Mapp, MD PhD, Helen Mar Fan, MD, Lesley Rawlings, PhD, Rachel Susman, Sue Morgan, FRACP, FRCPA, MBBS, Andrew H Wei, MBBS,PhD, Inderjeet Dokal, MD, Tom Vulliamy, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Deepak Singhal, MBBS, MD FRACP, FRCPA, Susan Branford, PhD, Elli Papaemmanuil, PhD, Jean Soulier, MDPhD, Stefan Fröhling, MD, Alwin Kramer, MD, Guy Sauvageau, MD PhD, Neil Morgan, Carolyn Owen, Csaba Bödör, PhD, Jude Fitzgibbon, Hugh Y. Rienhoff, Jr., MD, Mineo Kurokawa, MD PhD, Lucy Godley, MD PhD, Claude Preudhomme, Paul P Liu, MD PhD, Nicola Poplawski, MD, Christopher N. Hahn, PhD, Hamish S. Scott, PhD

Blood (2018) 132 (Supplement 1): 5241.

https://doi.org/10.1182/blood-2018-99-118017

Published: 2018

Journal Articles

Myeloid Malignancy Variant Curation Expert Panel: An ASH-Sponsored Clingen Expert Panel to Optimize and Validate Acmg/AMP Variant Interpretation Guidelines for Genes Associated with Inherited Myeloid Neoplasms

Blood (2018) 132 (Supplement 1): 5849.

https://doi.org/10.1182/blood-2018-99-118979

Published: 2018

Journal Articles

Differential Ex Vivo Sensitivity Patterns to Small-Molecule Inhibitors and Combination Therapies Among Acute Myeloid Leukemia Patients Harboring Both FLT3 and NPM1 Mutations

Christopher A. Eide, Stephen E Kurtz, PhD, Andy Kaempf, Andrew Park, Angela Rofelty, Beth Wilmot, PhD, Daniel Bottomly, Shannon K. McWeeney, PhD, Cristina E. Tognon, PhD, Motomi Mori, PhD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD

Blood (2017) 130 (Supplement 1): 1422.

https://doi.org/10.1182/blood.V130.Suppl_1.1422.1422

Published: 2017

Journal Articles

The Pro-Inflammatory Cytokine Interleukin-1 Is Essential for Clonal Expansion and Disease Progression in Acute Myeloid Leukemia

Alyssa Carey, BS, Megan M Cleary, B.S., B.A., David K Edwards, V, B.A., B.S., Christopher A. Eide, Elie Traer, MD PhD, Shannon K. McWeeney, PhD, Jeffrey W. Tyner, PhD, Grover C. Bagby, MD, Brian J. Druker, MD, Anupriya Agarwal, PhD

Blood (2015) 126 (23): 866.

https://doi.org/10.1182/blood.V126.23.866.866

Published: 2015

Journal Articles

Broad Activity of Apto-253 in AML and Other Hematologic Malignancies Correlates with KLF4 Expression Level

Stephen E. Kurtz, PhD, Daniel Bottomly, MS, Beth Wilmot, PhD, Shannon K. McWeeney, PhD, William Rice, PhD, Stephen B Howell, MD, Avanish Vellanki, Brian J. Druker, MD, Jeffrey W. Tyner, PhD

Blood (2015) 126 (23): 1358.

https://doi.org/10.1182/blood.V126.23.1358.1358

Published: 2015

Journal Articles

MS4A3 Improves Imatinib Response and Survival in BCR-ABL1 Primary TKI Resistance and in Blastic Transformation of Chronic Myeloid Leukemia

Anna M. Eiring, PhD, Jamshid S. Khorashad, MD PhD, Anupriya Agarwal, PhD, Clinton C. Mason, PhD, Fan Yu, MD, Hannah M. Redwine, Amber D. Bowler, Kevin C. Gantz, Kimberly R. Reynolds, MS, Phillip M. Clair, MS, David J. Anderson, MBA, Srinivas K Tantravahi, Shannon K. McWeeney, PhD, Brian J. Druker, MD, Derek L. Stirewalt, MD, Vivian G. Oehler, MD, Thomas O'Hare, PhD, Michael W. Deininger

Blood (2015) 126 (23): 14.

https://doi.org/10.1182/blood.V126.23.14.14

Published: 2015

Journal Articles

Exome Sequencing Informs Mechanisms of Clinical Resistance to the FLT3-D835 Inhibitor Crenolanib

Haijiao Zhang, MD, Kevin Matthew Watanabe-Smith, BS, Daniel Bottomly, MS, Beth Wilmot, PhD, Shannon K. McWeeney, PhD, Hagop M. Kantarjian, MD, Judy Ho, Jeremy Davis, Blake Pond, MS, Gautam Borthakur, MD, Abhijit Ramachandran, MS, Jorge E. Cortes, Robert Collins, MD, Jeffrey W. Tyner, PhD

Blood (2015) 126 (23): 2468.

https://doi.org/10.1182/blood.V126.23.2468.2468

Published: 2015

Journal Articles

CSF1R Inhibition Targets AML Cells By Depleting Supportive Microenvironmental Signal from CD14+ Monocytes

David K Edwards, V, B.A., B.S., Angela Rofelty, BS, Anupriya Agarwal, PhD, Stephen E Kurtz, PhD, Elie Traer, MD PhD, Patrice Lee, PhD, David Chantry, PhD, Marc Loriaux, MD PhD, Brian J. Druker, MD, Shannon K. McWeeney, PhD, Jeffrey W. Tyner, PhD

Blood (2015) 126 (23): 3824.

https://doi.org/10.1182/blood.V126.23.3824.3824

Published: 2015

Journal Articles

Activating Mutations of Insulin Receptor Substrate 2 (IRS2) in Patients with Tyrosine Kinase Inhibitor-Refractory Chronic Myeloid Leukemia

Samantha L Savage, Christopher A. Eide, Kyle F Concannon, Daniel Bottomly, MS, Beth Wilmot, PhD, Shannon K. McWeeney, PhD, Julia Elizabeth Maxson, PhD, Jeffrey W. Tyner, PhD, Cristina E. Tognon, PhD, Brian J. Druker, MD

Blood (2015) 126 (23): 2461.

https://doi.org/10.1182/blood.V126.23.2461.2461

Published: 2015

Journal Articles

A Transcriptomal Profile for Predicting Complete Cytogenetic Response (CCR) in Chronic Phase CML Patients Treated with Imatinib.

Shannon K. McWeeney, PhD, Lucy C. Pemberton, MD, Chris A. Harrington, PhD, Brian J. Druker, MD, Michael W. Deininger, MD, PhD

Blood (2007) 110 (11): 1007.

https://doi.org/10.1182/blood.V110.11.1007.1007

Published: 2007

NARROW

A Functional Profiling of Microenvironmental Factors and Small Molecules Reveals Monocyte Chemoattractant Protein-1 Mediates Drug Resistance in Acute Myeloid Leukemia

Evolution of Gilteritinib Resistance from Residual Disease to Relapse

Myeloid-Lineage Enhancers Drive Oncogene Synergy and Represent a Novel Therapeutic Target in CSF3R-CEBPA Mutant AML

Framework to Identify and Prioritize Candidate Inherited Myeloid Malignancy Germline Variants Leveraging the BEAT AML Cohort

Genome-Wide CRISPR Screening in Acute Myeloid Leukemia Cells Identifies Genes in the PI3K/AKT/mTOR and MEK/ERK Pathways That Define Sensitivity to Trametinib

Discovery & Characterization of Therapeutically Targetable Ntrk Point Mutations in Leukemia

Genome-Wide CRISPR Screening Identifies MAPK and Mtorc Pathways As Regulators of Sorafenib Resistance in Acute Myeloid Leukemia

Immunogenomic Exploration of the Acute Myeloid Leukemia Microenvironment Identifies Determinants of T-Cell Fitness

Combining p38MAPK Inhibitors with a Second Targeted Agent Enhances Blockade of Inflammatory Signaling-Mediated Survival in Acute Myeloid Leukemia Cells

Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB

Myeloid Malignancy Variant Curation Expert Panel: An ASH-Sponsored Clingen Expert Panel to Optimize and Validate Acmg/AMP Variant Interpretation Guidelines for Genes Associated with Inherited Myeloid Neoplasms

Differential Ex Vivo Sensitivity Patterns to Small-Molecule Inhibitors and Combination Therapies Among Acute Myeloid Leukemia Patients Harboring Both FLT3 and NPM1 Mutations

The Pro-Inflammatory Cytokine Interleukin-1 Is Essential for Clonal Expansion and Disease Progression in Acute Myeloid Leukemia

Broad Activity of Apto-253 in AML and Other Hematologic Malignancies Correlates with KLF4 Expression Level

MS4A3 Improves Imatinib Response and Survival in BCR-ABL1 Primary TKI Resistance and in Blastic Transformation of Chronic Myeloid Leukemia

Exome Sequencing Informs Mechanisms of Clinical Resistance to the FLT3-D835 Inhibitor Crenolanib

CSF1R Inhibition Targets AML Cells By Depleting Supportive Microenvironmental Signal from CD14+ Monocytes

Activating Mutations of Insulin Receptor Substrate 2 (IRS2) in Patients with Tyrosine Kinase Inhibitor-Refractory Chronic Myeloid Leukemia

A Transcriptomal Profile for Predicting Complete Cytogenetic Response (CCR) in Chronic Phase CML Patients Treated with Imatinib.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only